Crohn’s Disease - Pipeline Insight, 2021

Crohn’s Disease - Pipeline Insight, 2021

  • May 2021 •
  • 150 pages •
  • Report ID: 6089318 •
  • Format: PDF
“Crohn’s Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Crohn’s Disease Understanding

Crohn’s Disease: Overview
Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease. Initially only a small segment of the gastrointestinal tract may be involved, but Crohn’s disease has the potential to progress extensively.
The disease can be witnessed in any age group; however, it is seen to be developing mostly in between 20 and 30 years of age. About one-sixth of patients present before the age of 15 and often with severe disease. The exact pathogenesis of CD is unknown, although there are a number of genetic and environmental factors that have been shown to increase the risk of the disease and lead to the aberrant gut immune response characteristic of the disease.
Crohn’s is a chronic illness that requires expensive medications, often hospitalization and/or surgery, and results in a heavy social and economic toll. Based on its phenotypic progression, Crohn’s can be characterized as inflammatory, fibrostenotic, or fistulizing, and may progress to extraintestinal or systemic manifestations. The broad clinical spectrum of the disease portends a diagnostic challenge, and requires a multi-disciplinary approach to provide the appropriate management. Various treatments and therapies are available that help in order to ease away the symptoms related to Crohn’s disease. Treatment of Crohn’s disease is guided by severity, behavior, and disease location, along with anatomic site, appearance of complications, treatment refractoriness and dependency to steroids.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Crohn’s Disease R&D. The therapies under development are focused on novel approaches for Crohn’s Disease.

Crohn’s Disease Emerging Drugs Chapters
This segment of the Crohn’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Crohn’s Disease Emerging Drugs
• Filgotinib: Gilead Sciences
Filgotinib is an orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells.
In December 2020 Gilead and Galapagos announced new commercialization and development agreement for Jyseleca (Filgotinib). The announcement followed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for filgotinib in the treatment of RA. It is currently in Phase III stage of development for Crohn’s Disease.
• Risankizumab: Abbvie
Risankizumab is a humanized, monoclonal IgG1 class antibody whose action is based on binding to the p19 subunit of IL-23. After binding to the antibody, IL-23 is selectively blocked, thus inhibiting its pro-inflammatory activity. Risankizumab (ABBV-066) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn’s disease, ulcerative colitis, atopic dermatitis psoriatic arthritis and Hidradenitis Suppurativa. It is currently in Phase III stage of development for Crohn’s Disease.
In November 2016, Abbvie receives Orphan Drug Designation for investigational IL-23 inhibitor risankizumab from the U.S. Food and Drug Administration for the treatment of pediatric patients with crohn’s disease.
Further product details are provided in the report……..

Crohn’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Crohn’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Crohn’s Disease
There are approx. 80+ key companies which are developing the Crohn’s Disease. The companies which have their Crohn’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Gilead Sciences.
• Phases
This report covers around 90+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Crohn’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Crohn’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Crohn’s Disease drugs.

Crohn’s Disease Report Insights
• Crohn’s Disease Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Crohn’s Disease Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Crohn’s Disease drugs?
• How many Crohn’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Crohn’s Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Crohn’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Crohn’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Gilead Sciences
• Abbvie
• Eli Lilly and Company
• Celgene
• AstraZeneca
• Mesoblast
• Alfasigma
• Tiziana Life Sciences
• Pfizer
• Dermavant Sciences GmbH
• Cytocom
• Amgen
• Priothera
• SLA Pharma
• HAV Vaccines Ltd
• Enzo Biochem
• VHsquared Ltd.
• Stero Biotechs
• Reistone Biopharma Company Limited
• Qu Biologics
• Provention Bio
• Mitsubishi Tanabe Pharma Corporation
• Takeda Pharmaceuticals
• Soligenix
• Immunic
• Atlantic Healthcare
• 4D Pharma
• Landos Biopharma
• Janssen
• Protagonist Therapeutics
• Roche
• Eisai
• Bristol-Myers Squibb
• Iltoo Pharma
• Fast Forward Pharmaceuticals
• Suzhou Connect Biopharmaceuticals
• Theravance Biopharma
• TaiwanJ Pharmaceuticals
• Active Biotech
• Celularity
• Alpha Cancer Technologies
• Koutif Therapeutics
• Winston Pharmaceuticals
• Tract Therapeutics
• Trio medicines
• Tetherex Pharmaceuticals
• ChemoCentryx
• Algernon Pharmaceuticals
• Neuclone

Key Products
• Filgotinib
• Risankizumab
• Mirikizumab
• Ozanimod
• Brazikumab
• Risankizumab
• Upadacitinib
• Remestemcel-L
• Rifaximin
• Foralumab
• ABX464
• Etrasimod
• CYTO-201
• Masitinib
• Mocravimod
• Ortem Topical metronidazole
• HAV anti-MAP vaccine
• Alequel
• V565
• Cannabidiol
• SHR0302
• QBECO-SSI
• PRV-6527
• PF-06651600
• MT-1303
• TAK-018
• SGX203
• IMU 838
• Brepocitinib
• Alicaforsen
• Bacteroides thetaiotaomicron
• BT-11
• JNJ-64304500
• PTG-200
• RG-7880
• E6011
• BMS-986165
• Spesolimab
• Aldesleukin
• FFP104
• CBP-307
• TD-1473
• JKB-122
• Laquinimod
• PDA-001
• IMU-856
• ACT-101
• KT-1002
• Civamide
• TregCel
• TR8
• SelK2
• CCX507
• NP-178
• NeuLara